At what enterprise value was STEPHID acquired in 2023?

You can find the full valuation details of STEPHID on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of STEPHID when it was acquired by ANJAC BEAUTY & HEALTH?

The exact EV/EBITDA multiple for STEPHID is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was STEPHID acquired by ANJAC BEAUTY & HEALTH?

STEPHID was acquired by ANJAC BEAUTY & HEALTH in 2023.

What was the revenue of STEPHID at the time of the deal?

The revenue of STEPHID at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the STEPHID acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STEPHID deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.anjac.com/app/uploads/2023/11/CP-FR-ANJAC-STEPHID_231114.pdf

← DATABASE

Home Database Healthcare & PharmaSTEPHID

11/2023

STEPHID acquired by ANJAC BEAUTY & HEALTH

FRANCE Life Sciences / Pharma & Biotech / CDMO REV 5M - 25M EUR

Context

ANJAC acquired STEPHID to diversify its industrial portfolio into the high-growth luxury fragrance and "niche" perfumery segments. This marks the group's 10th acquisition in six years. The integration allows ANJAC to offer "complementary expertise" (skincare + fragrance) to its existing premium client base. STEPHID benefits from ANJAC's industrial scale to fund capacity expansion while retaining its artisanal identity and current governance.

STEPHID, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1989, STEPHID is a French specialist in the manufacturing, filling, and packaging of luxury perfumes. It serves over 60 high-notoriety brands, specializing in small series and complex manual operations (refined dressings and precise bottle finishing). The company also offers end-to-end logistics for global distribution of finished luxury goods.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
01/2024	MERCK & CO.	HARPOON THERAPEUTICS	UNITED STATES	R&D Biotech
12/2023	MARLE GROUP	NOWAK	FRANCE	Implants & Prosthetics
11/2023	AMETEK	PARAGON MEDICAL	UNITED STATES	Medical Devices
10/2023	RESONETICS	NITINOL BUSINESS	UNITED STATES	Medical Devices
10/2023	LUXEMPART	ALPHACAPS	GERMANY	Nutrition & Dietary Supplements
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Medical Consumables
08/2023	OAKLEY CAPITAL INVESTMENTS	LIBERTY DENTAL GROUP	GERMANY	Implants & Prosthetics
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
07/2023	ELOS MEDTECH	KLINGEL MEDICAL GROUP	GERMANY	Implants & Prosthetics
07/2023	EQT PARTNERS / ADIA	DECHRA PHARMACEUTICALS	UNITED KINGDOM	Pharma & Biotech

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STEPHID by ANJAC BEAUTY & HEALTH are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.